OverviewChartNewsTraderScreen

Morgan Stanley Call 230 COR 20.09.../  DE000ME17P95  /

Stuttgart
14/06/2024  11:22:44 Chg.+0.06 Bid16:01:57 Ask16:01:57 Underlying Strike price Expiration date Option type
1.06EUR +6.00% 1.11
Bid Size: 25,000		 1.14
Ask Size: 25,000		 Cencora Inc 230.00 USD 20/09/2024 Call
GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 28/05 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire 15/05 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire 13/05 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire 09/05 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire 02/05 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 29/04 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire 17/04 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire 15/04 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
GlobeNewswire 22/03 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire 18/03 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire 18/03 Parexel Announces CEO Succession Plan
GlobeNewswire 12/03 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
GlobeNewswire 14/02 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire 23/01 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire 02/01 Coherus Announces U.S. Launch of LOQTORZI™
GlobeNewswire 22/12/2023 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire 19/12/2023 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...
GlobeNewswire 06/12/2023 Outlook Therapeutics® Announces Strategic Organizational Realignment
GlobeNewswire 27/11/2023 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...
GlobeNewswire 14/11/2023 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...
GlobeNewswire 02/11/2023 Outlook Therapeutics® Provides Update on Type A Meetings with FDA
GlobeNewswire 01/11/2023 Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...
Newsfile Corp 26/10/2023 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
GlobeNewswire 29/09/2023 Outlook Therapeutics® Requests Type A Meeting With FDA